查詢結果分析
相關文獻
- TEL/AML1 Fusion Gene in Childhood Acute Lymphoblastic Leukemia in Southern Taiwan
- Development of Acute Lymphoblastic Leukemia in a Child after Treatment of Langerhans Cell Histiocytosis: Report of One Case
- 成年急性淋巴性白血病之現況
- Genetic Studies in Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia in Young Adults: Two Chemotherapeutic Protocols for the Treatment of 46 Patients
- Intelligence Quotient in Childhood Acute Lymphoblastic Leukemia after Prophylactic Treatment in Central Nervous System with 18 Gy Cranial Irradiation and Intrathecal Methotrexate
- Acute Lymphoblastic Leukemia Occurring as a Second Malignant Neoplasm in a Child
- 照顧一位急性淋巴性白血病學齡期兒童的護理經驗
- 成人型急性淋巴性白血病復發以視神經病變為初始表徵--病例報告
- Allogeneic Bone Marrow Transplantation for Children with Acute Lymphoblastic Leukemia in Second Remission or Relapse
頁籤選單縮合
題 名 | TEL/AML1 Fusion Gene in Childhood Acute Lymphoblastic Leukemia in Southern Taiwan=TEL/AML1融合基因在南臺灣兒童急性淋巴性白血病的表現情形 |
---|---|
作 者 | 林佩瑾; 張泰琮; 林綉茹; 邱世欣; 章人欽; 沈俊明; | 書刊名 | The Kaohsiung Journal of Medical Sciences |
卷 期 | 24:6 2008.06[民97.06] |
頁 次 | 頁289-296 |
分類號 | 417.5515 |
關鍵詞 | 急性淋巴性白血病; 聚合鍊鎖反應; TEL/AML1融合基因; Acute lymphoblastic leukemia; Polymerase chain reaction; TEL/AML1 fusion gene; |
語 文 | 英文(English) |
中文摘要 | 百分之八十至九十的兒童急性淋巴性白血病個案會出現染色體的異常,這些白血病特異性的染色體變異不僅具有預後的價值,還能提供研究白血病生成、轉型及增生機轉的線索。分子生物學的進步使得這些染色體變化可以經由高敏感度的方法偵測出來。在本研究中我們使用反轉錄酶聚合鍊鎖反應的技術來偵測白血病特異性融合基因 TEL/AML1,並且在治療過程中監測它的表現量的變化。共有二十五位急性淋巴性白血病個案納入研究,包括二十位新診斷個案及五位復發的個案。出現 TEL/AML1 融合基因的比率是 32%,TEL/AML1 融合基因陽性的個案臨床表現和其它研究報告相似。其中六位在治療過程中持續監測 TEL/AML1 融合基因的表現量,有四位的表現量隨著治療明顯下降。未來需要更大型的研究以進一步證實使用 TEL/AML1 融合基因為追蹤治療效果的標記是可行的。 |
英文摘要 | Chromosomal abnormalities are found in 80-90% of childhood cases of acute lymphoblastic leukemia (ALL). Leukemia-specific chromosome aberrations not only have prognostic value, but also provide important clues for further investigation into leukogenesis, leukemic cell transformation, and proliferation. This study used reverse transcriptase-polymerase chain reaction techniques to detect transcripts of the leukemia-specific chromosome fusion gene, TEL/AML1, and to monitor the expression levels of the TEL-AML1 fusion transcript in ALL patients at sequential intervals during their treatment course. Twenty-five ALL patients were enrolled, including 20 who were newly diagnosed and five in relapse. The incidence of the TEL/AML1 fusion gene in this study was 32%. The clinical features of our eight TEL/AML1-positive ALL cases were similar to those in other studies. Blotting analysis of the levels of the TEL-AML1 fusion transcript was used to detect minimal residual disease. Reduced levels of TEL/AML1 expression were found in four of the six patients whose bone marrow or peripheral blood samples were obtained after treatment. Further investigation with a larger sample size is warranted. |
本系統中英文摘要資訊取自各篇刊載內容。